摘要
目的探讨自体外周血造血干细胞移植（auto-PBSCT）治疗非霍奇金淋巴瘤（NHL）的疗效和安全性。方法行自体造血干细胞移植的16例NHL患者,其中移植前达到完全缓解状态8例（治疗组）,男性3例,女性5例,平均年龄29.6岁（6~42岁）;移植前为复发难治性8例（对照组）。预处理均采用经典的BEAM方案（卡莫司汀、依托泊苷、阿糖胞苷、马法兰）。移植后观察全部患者移植相关并发症发生情况和生存情况。结果治疗组全部患者均获造血重建,随访至2015年10月,中位随访时间为32.1个月（0.8~67个月）,治疗组除1例死于严重肺部感染外,其余7例全部处于完全缓解状态,总生存率（OS）达87.5%;对照组中1例死于多器官功能衰竭,1例死于肺部感染,2例死于败血症,2例复发死亡,2例患者存活,OS达25.0%。两组OS相比,差异有统计学意义（χ2=6.349,P=0.012）。结论 Auto-PBSCT对于移植前完全缓解的患者有效、安全,对于复发难治性非霍奇金淋巴瘤,可作为挽救性治疗,在临床广泛开展。
Objective To explore the efficacy and safety of autologous peripheral blood stem cell transplantation（autoPBSCT） for non-Hodgkin lymphoma（NHL）.Methods Retrospective analysis of 16 patients with non-Hodgkin lymphoma who underwent autologous hematopoietic stem cell transplantation were conducted.Before transplantation,8 cases reached complete remission（treatment group）,3 males and 5 females,with the average age of 29.6 years（6 ~ 42 years）.Before transplantation,there had 8 relapse and refractory cases（control group）.Pretreatment was conducted with the classical BEAM regimen（carmustine、etoposide、cytarabine、melphalan）.After transplantation,the related complications and survival were observed.Results All cases acquired hematopoietic reconstitution in the treatment group,Follow up till October 2015,1 case died of severe pulmonary infection in the treatment group,the overall survival rate（OS） was 87.5%.In the control group,1 case died of multiple organ failure and 1 case died of pulmonary infection,2 cases died of sepsis,1 case died of post transplant lymphatic proliferative disease,2 cases died of relapse and 2 cases survived,the OS was 25.0%.The difference was statistically significant（χ~2=6.349,P=0.012） between the 2 groups.Conclusion Auto-PBSCT is effective and safe for patients with complete remission before transplantation,and it also can be used as salvage therapy for relapsed and refractory non-Hodgkin lymphoma and can be carried out in clinical extensively.
出处
《实用癌症杂志》
2016年第10期1613-1616,共4页
The Practical Journal of Cancer
基金
国家自然科学基金(编号:31200686)
关键词
自体外周血造血干细胞移植
非霍奇金淋巴瘤
BEAM方案
总生存率
Autologous peripheral blood stem cell transplantation（auto-PBSCT）
Non-Hodgkin lymphoma
BEAM regimen
Overall survival rate
